Latigo Biotherapeutics has whipped together a $150 million series B fundraising round to advance a pipeline of non-opioid ...

Vertex Pharma's non-opioid painkiller suzetrigine was unable to perform better than placebo in a phase 2 trial in lumbosacral radiculopathy (LSR), a form of neuropathic back pain, ahead of an FDA ...

Pain is an area with limited treatment options ... Last year’s Alpine acquisition added povetacicept to Vertex’s pipeline, which Vertex believes has a “pipeline in a product” potential.

A decade from now, considering Vertex's pipeline, the company could potentially ... common problem that has limited treatment options: pain. Today's over-the-counter choices sometimes aren't ...

Merck should be a useful partner for these, since it already has three oncology drugs on the market and eight in clinical trials in its pipeline. Journavx, Vertex’s nonopioid pain-signal ...

transfusion-dependent beta thalassemia and acute pain, and it continues to advance clinical and research programs in these areas. Vertex also has a robust clinical pipeline of investigational ...

The non-opioid nature of Journavx is expected to be a key differentiator in a market that is increasingly seeking alternatives to traditional opioid-based pain medications. Vertex’s pipeline ...

Pacira BioSciences, Inc.'s stock is up 33%, backed by a new Exparel patent, growth strategies, and market trends. Click here to read why PCRX stock is a Buy.

The company also showed its strengths beyond this specialty area, collecting approvals for a gene-editing therapy for blood disorders a little over a year ago and a pain treatment just ... A decade ...

The company’s focus on innovation and pipeline expansion has allowed it to maintain this dominant position despite potential competitive pressures. The launch of Journavx represents Vertex’s entry ...

The company also showed its strengths beyond this specialty area, collecting approvals for a gene-editing therapy for blood disorders a little over a year ago and a pain treatment just recently.